Retrospective Cohort Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2024; 30(33): 3823-3836
Published online Sep 7, 2024. doi: 10.3748/wjg.v30.i33.3823
Pan-immune-inflammation value as a prognostic biomarker for colon cancer and its variation by primary tumor location
Qian-Yu Wang, Wen-Tao Zhong, Yi Xiao, Guo-Le Lin, Jun-Yang Lu, Lai Xu, Guan-Nan Zhang, Jun-Feng Du, Bin Wu
Qian-Yu Wang, Yi Xiao, Guo-Le Lin, Jun-Yang Lu, Lai Xu, Guan-Nan Zhang, Bin Wu, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Wen-Tao Zhong, Jun-Feng Du, Medical Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Co-corresponding authors: Jun-Feng Du and Bin Wu.
Author contributions: Wang QY and Wu B conceived the concept; Wang QY and Zhong WT collected the cohort data; Du JF and Wu B contributed to the reagents/materials/analysis tools; Wang QY wrote the original draft; Xiao Y, Lin GL, Lu JY, Xu L, Zhang GN, Du JF, and Wu B reviewed and edited the manuscript. Du JF and Wu B contributed to the supervision of this manuscript and should be considered as co-corresponding authors. All authors contributed to the article and approved the submitted version.
Supported by National High Level Hospital Clinical Research Funding, No. 2022-PUMCH-B-003.
Institutional review board statement: The ethics committee of Peking Union Medical College Hospital (I-24PJ0585) approved this study.
Informed consent statement: Owing to the anonymity and retrospective nature of the data, the requirement for written informed consent was waived.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets used and/or analyzed in the current study presented in the study are included in the article/supplementary information section. Further inquiries can be directed to the corresponding author (Bin Wu, E-mail: Wubin@pumch.cn) upon reasonable request.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bin Wu, MD, Chief Doctor, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan Road, Wangfujing, Dongcheng District, Beijing 100730, China. wubin@pumch.cn
Received: July 10, 2024
Revised: August 2, 2024
Accepted: August 19, 2024
Published online: September 7, 2024
Processing time: 53 Days and 16.2 Hours
Core Tip

Core Tip: This study underscores the critical role of tumor location in shaping the prognostic significance of the pan-immune-inflammation value in colon cancer patients. The findings reveal that a high pan-immune-inflammation value is strongly correlated with poorer disease-free survival in patients with left-sided colon cancer, while no such association was observed in right-sided colon cancer. These results suggest that integrating tumor location into prognostic evaluations could improve the identification of high-risk patients and facilitate more precise, personalized treatment strategies in clinical practice.